pertuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	4957	380610-27-5

Description:

Molecule	Description
Synonyms: pertuzumab perjeta rhuMAb 2C4 pertuzumab (genetical recombination)	a humanized HER-2 monoclonal antibody; prevents ERBB2 receptor protein from binding (dimerizing) to other receptors in the HER family Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

pertuzumab
perjeta
rhuMAb 2C4
pertuzumab (genetical recombination)

a humanized HER-2 monoclonal antibody; prevents ERBB2 receptor protein from binding (dimerizing) to other receptors in the HER family

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
June 28, 2013	PMDA	Chugai Pharmaceutical
June 8, 2012	FDA	GENENTECH
March 4, 2013	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	1584.12	18.45	618	47992	23085	63417327
Diarrhoea	1345.21	18.45	2136	46474	713230	62727182
Ejection fraction decreased	1043.93	18.45	451	48159	21881	63418531
Neuropathy peripheral	626.91	18.45	589	48021	113078	63327334
Disease progression	601.45	18.45	596	48014	122162	63318250
Metastases to central nervous system	548.45	18.45	245	48365	12860	63427552
Polyneuropathy	510.96	18.45	241	48369	14348	63426064
Febrile neutropenia	442.58	18.45	498	48112	117951	63322461
Mucosal inflammation	371.19	18.45	299	48311	46629	63393783
Neutropenia	361.04	18.45	549	48061	174456	63265956

Showing 1 to 10 of 273 entries

Previous1 2 3 4 5…28Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Delusion of grandeur	144.91	62.75	28	1745	1132	34954026
Rhinalgia	110.65	62.75	22	1751	1031	34954127
Affective disorder	107.99	62.75	28	1745	4332	34950826
Schizophrenia	88.97	62.75	28	1745	8638	34946520
Lymphocyte count abnormal	84.59	62.75	18	1755	1180	34953978
Hallucination, auditory	80.22	62.75	28	1745	11889	34943269
Extrapyramidal disorder	78.09	62.75	28	1745	12852	34942306
Incorrect dose administered	75.28	62.75	38	1735	40477	34914681
SARS-CoV-2 test positive	72.86	62.75	22	1751	5911	34949247
Neutrophil count increased	70.29	62.75	28	1745	17118	34938040

Showing 1 to 10 of 13 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	1313.88	18.59	571	42964	39725	79661128
Diarrhoea	1022.78	18.59	1759	41776	878730	78822123
Ejection fraction decreased	730.44	18.59	363	43172	34214	79666639
Neuropathy peripheral	551.66	18.59	520	43015	140785	79560068
Metastases to central nervous system	430.92	18.59	200	43335	16175	79684678
Polyneuropathy	393.26	18.59	213	43322	23938	79676915
Disease progression	364.31	18.59	475	43060	183887	79516966
Mucosal inflammation	309.67	18.59	286	43249	75294	79625559
Febrile neutropenia	261.37	18.59	459	43076	230540	79470313
Neutropenia	243.24	18.59	505	43030	287205	79413648

Showing 1 to 10 of 259 entries

Previous1 2 3 4 5…26Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01FD02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
ATC	L01XY02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Combinations of antineoplastic agents
FDA EPC	N0000175661	HER2/neu Receptor Antagonist
FDA MoA	N0000020008	HER2/Neu/cerbB2 Antagonists
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
HER2-positive rectal cancer	indication	363351006	DOID:1993
HER2-positive colon cancer	indication	363406005	DOID:219
HER2-positive carcinoma of breast	indication	427685000

Showing 1 to 3 of 3 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	ANTIBODY BINDING				UNKNOWN	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
014427	NDDF
1298944	RXNORM
190566	MMSL
28589	MMSL
4031566	VUID
4031566	VANDF
5046	IUPHAR_LIGAND_ID
704226002	SNOMEDCT_US
704227006	SNOMEDCT_US
8380	INN_ID

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PERJETA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-145	INJECTION, SOLUTION, CONCENTRATE	30 mg	INTRAVENOUS	BLA	31 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-245	INJECTION, SOLUTION	1200 mg	SUBCUTANEOUS	BLA	30 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-245	INJECTION, SOLUTION	1200 mg	SUBCUTANEOUS	BLA	30 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-260	INJECTION, SOLUTION	600 mg	SUBCUTANEOUS	BLA	30 sections
Phesgo	HUMAN PRESCRIPTION DRUG LABEL	3	50242-260	INJECTION, SOLUTION	600 mg	SUBCUTANEOUS	BLA	30 sections

Showing 1 to 5 of 5 entries

Previous1Next